DIGITAL-COOPERATION
27.5.2024 20:23:30 CEST | Business Wire | Press release
The Digital Cooperation Organization (DCO), a global multilateral organization committed to enabling digital prosperity for all by accelerating the sustainable and inclusive growth of the digital economy, announced the launch of EconomiX magazine, a publication offering insights from international digital economy thought leaders into ways nations and organizations can seize the digital economy’s opportunities to spur digital transformation globally. By merging insights from different stakeholders from the public and private sectors, academia, and international organizations from DCO Member States and other countries, EconomiX provides a holistic view of the digital economy from different perspectives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527424476/en/
1st Issue of the “EconomiX by the DCO” magazine (Graphic: AETOSWire)
The first edition of EconomiX covers a wide range of topics including global news on the digital economy, updates from DCO Member States, special articles on "Developing new AI business models" and "Digital upskilling -future-proof jobs". The theme of the magazine's first issue "Growth Unleashed - AI: Powering Economic Prosperity" delves into the world of artificial intelligence and its transformative impact on economies worldwide.
In addition to exclusive interviews with H.E. Dr. Bosun Tijani, Minister of Communications, Innovation and Digital Economy of the Federal Republic of Nigeria, and H.E. Paula Ingabire, Minister of Information and Communications Technology and Innovation of the Republic of Rwanda, and Ms. Deemah AlYahya, Secretary-General of the DCO, this issue features articles and interviews with a distinguished group of ministers, CEOs, and experts in technology and the digital economy.
Manel Bondi, DCO’s Chief of Digital Markets Growth, commented: "EconomiX stands as a catalyst for change and empowerment amidst the digital revolution. It fills an important gap with its focus on the economic dimension of technology as a key pillar to drive and sustain inclusive and meaningful economic growth across the globe. It demonstrates how communities, businesses, and governments can cooperate meaningfully and pave the way toward achieving digital prosperity for all. EconomiX is a platform that fosters knowledge sharing, innovation, and inspiration for our readers, and reflects our dedication to promoting cooperation to develop the global digital economy."
Addressing critical aspects of digital economic advancement like policy making, data transformation, digital updates, women empowerment, and thought leadership, EconomiX endeavors to guide its readers through the digital revolution. It aims to provide actionable insights, expert analysis, and case studies for navigating digital change, fostering an understanding of how to leverage digital transformation for economic and social prosperity.
The magazine is a vital tool for digital transformation, aimed at empowering change by fostering knowledge exchange, enhancing cooperation, uplifting social prosperity, and stimulating innovation. It presents global trends and innovations, advocates for inclusive digital transformation, and fosters a community of leaders shaping the digital future. It also highlights the DCO's impactful initiatives and showcases success stories from the network. Available in both digital and print formats, it is an invaluable resource for those committed to making a significant impact in the digital realm. https://www.dco.org/economix
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240527424476/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom